Compare Honeywell International Inc (HON) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Tango Therapeutics Inc. — how do they compare? Honeywell International Inc trades at $208.11 (market cap $65.70B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Honeywell International Inc is far larger — about 17.5× Tango Therapeutics Inc.'s market cap, and Honeywell International Inc pays a 1.35% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 91 Days and Tango Therapeutics Inc. for 0 Days on average.
| HON | TNGX | |
|---|---|---|
Market Cap | $65.70B | $3.75B |
Volume | 1,861,268 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $248.79 | $32.90 |
52-Week Low | $188.14 | $7.50 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $90.49B | $2.77B |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $207.29, down 1.12% on the day, with bearish technical signals but strong fundamental metrics including a low P/E of 7.97 and robust ROE of 47.43%. The company recently completed its transformation into a pure-play automation business following spin-offs and secured a significant $300 million refinery project with Dangote. Earnings have consistently beaten expectations in recent quarters, with Q3 2026 results expected on October 22.
HON presents a compelling value opportunity with attractive valuation multiples and strong profitability, though near-term technical weakness and increasing debt levels warrant caution. Analyst consensus remains strongly bullish with a $259.25 price target representing 25% upside potential. The company's refocused automation strategy and recent contract wins provide growth catalysts, while execution risks and macroeconomic sensitivity pose challenges.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
